Search


Current filters:






Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 11 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2016Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort studyOwen, C.; Ngian, G.; Elford, K.; Moore, O.; Stevens, W.; Nikpour, M.; Rabusa, C.; Proudman, S.; Roddy, J.; Zochling, J.; Hill, C.; Sturgess, A.; Tymms, K.; Youssef, P.; Sahhar, J.
2016Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACSKhazanie, P.; Hammill, B.G.; Patel, C.B.; Kiernan, M.S.; Cooper, L.B.; Arnold, S.V.; Fendler, T.J.; Spertus, J.A.; Curtis, L.H.; Hernandez, A.F.
2014Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC.20 randomized trialChow, E.; Meyer, R.; Chen, B.; van der Linden, Y.; Roos, D.; Hartsell, W.; Hoskin, P.; Wu, J.; Nabid, A.; Tissing-Tan, C.; Oei, B.; Babington, S.; Demas, W.; Wilson, C.; Wong, R.; Brundage, M.
2013Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomesCho, Y.; Badve, S.; Hawley, C.; McDonald, S.; Brown, F.; Boudville, N.; Bannister, K.; Clayton, P.; Johnson, D.
2015Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three yearsWabe, N.; Sorich, M.; Wechalekar, M.; Cleland, L.; McWilliams, L.; Lee, A.; Spargo, L.; Metcalf, R.; Hall, C.; Proudman, S.; Wiese, M.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2011Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsKantarjian, H.; Giles, F.; Bhalla, K.; Pinilla-Ibarz, J.; Larson, R.; Gattermann, N.; Ottmann, O.; Hochhaus, A.; Radich, J.; Saglio, G.; Hughes, T.; Martinelli, G.; Kim, D.; Shou, Y.; Gallagher, N.; Blakesley, R.; Baccarani, M.; Cortes, J.; le Coutre, P.
2012Effects of biocompatible versus standard fluid on peritoneal dialysis outcomesJohnson, D.; Brown, F.; Clarke, M.; Boudville, N.; Elias, T.; Foo, M.; Jones, B.; Kulkarni, H.; Langham, R.; Ranganathan, D.; Schollum, J.; Suranyi, M.; Tan, S.; Voss, D.
2011Effect of dialysis modality on survival of hepatitis C-infected ESRF patientsBose, B.; McDonald, S.; Hawley, C.; Brown, F.; Badve, S.; Wiggins, K.; Bannister, K.; Boudville, N.; Clayton, P.; Johnson, D.